These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9178144)

  • 21. Erythropoietin associated hypertension among pediatric dialysis patients.
    Komatsu Y; Ito K
    Adv Perit Dial; 1992; 8():448-52. PubMed ID: 1361845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Maintenance therapy on the anemia in continuous ambulatory peritoneal dialysis (CAPD) patients using subcutaneous administration of recombinant human erythropoietin fortnightly--a multicenter trial].
    Kubota M; Kawaguchi Y; Nomoto Y; Tsuchida H; Nihei H; Kubo K; Omori Y; Babazono T; Ogura Y; Hara S
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1081-90. PubMed ID: 8230819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
    Glaspy J; Jadeja JS; Justice G; Kessler J; Richards D; Schwartzberg L; Rigas J; Kuter D; Harmon D; Prow D; Demetri G; Gordon D; Arseneau J; Saven A; Hynes H; Boccia R; O'Byrne J; Colowick AB
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):17-23. PubMed ID: 11308270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
    Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
    Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration.
    Lubrich-Birkner I; Schollmeyer P; Steinhauer HB
    Adv Perit Dial; 1990; 6():302-7. PubMed ID: 1982833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease.
    Salvarani C; Lasagni D; Casali B; Macchioni P; Boiardi L; Rossi F; Rivasi P; Portioli I
    J Rheumatol; 1991 Aug; 18(8):1168-71. PubMed ID: 1941817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants.
    Meister B; Maurer H; Simma B; Kern H; Ulmer H; Hittmair A; Fink FM
    Stem Cells; 1997; 15(5):359-63. PubMed ID: 9323798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.
    Swanepoel CR; Moosa MR; Rowland GF; Meyers AM; Botha BP; Smart AJ; Goodman R; Schall R; Keogh HJ; Merrifield EH
    S Afr Med J; 1996 Oct; 86(10):1266-9. PubMed ID: 8955732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
    Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term therapy with recombinant human erythropoietin decreases percentage of CD152(+) lymphocytes in primary glomerulonephritis haemodialysis patients.
    Trzonkowski P; Myśliwska J; Debska-Slizień A; Bryl E; Rachoń D; Myśliwski A; Rutkowski B
    Nephrol Dial Transplant; 2002 Jun; 17(6):1070-80. PubMed ID: 12032199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis.
    Lai PC; Wu MS; Huang JY; Huang CC; Leu ML
    Changgeng Yi Xue Za Zhi; 1994 Jun; 17(2):105-12. PubMed ID: 8069732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of recombinant human erythropoietin treatment on cortisol responses to insulin-induced hypoglycemia in CAPD patients.
    Díez JJ; Iglesias P; Sastre J; Gómez-Pan A; Selgas R; Romero JR; Méndez J
    Adv Perit Dial; 1993; 9():336-41. PubMed ID: 8105958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.